Head-to-head · free

Stryker Corporation vs Thermo Fisher Scientific

SYK vs TMO — return on capital, cash generation, margins and balance sheet side by side.

SYK

7 / 10

measures where SYK leads

TMO

3 / 10

measures where TMO leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureSYK · FY2025TMO · FY2025
Revenue$5.9B$44.6B
Net income$654.0M$6.7B
Revenue growth (yearly, multi-year)10.4%3.2%
Free cash flow$4.3B$6.3B
Free cash flow margin73.0%14.1%
Net cash / (debt)——
ROIC9.6%8.3%
Return on equity15.1%13.0%
Gross margin64.0%40.9%
Operating margin20.1%18.2%
Net debt / EBITDA1.95x2.81x

Figures are as reported by each company; latest fiscal year shown.

Where Stryker Corporation's cash went (FY2025)

Capital spending
$761.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full SYK profile →

Where Thermo Fisher Scientific's cash went (FY2025)

Capital spending
$1.5B
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TMO profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons